Price chart (1D to 10Y)
Licensed market data — shown to members, not published to the open web.
Valuation vs Instaport thresholds (P/E, PEG, P/FCF, P/S)
Licensed market data — shown to members, not published to the open web.
Profile
From SEC filingsCompany description
We are a biopharmaceutical company using our proprietary Precision Timed Release™ (“PTR™ ”) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. With an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (“ADHD”) and anxiety, we are identifying and evaluating additional therapeutic areas where our PTR technology may be employed to develop future product candidates. Our PTR platform incorporates a proprietary Erosion Barrier Layer (“EBL”) designed to allow for the release of drug substance at specific, pre-defined time intervals, unlocking the potential for once-daily, multi-dose tablets. We are targeting the ADHD treatment market, with an estimated US market size of approximately 100 million annual prescriptions of stimulants, as of September 2025. Furthermore, the average branded long-acting stimulant wholesale acquisition cost (WAC) is $495/Rx. It is reasonable to assume that a 1% market share capture would represent approximately $250 to $300 million in annual revenue less rebates and discounts in this marketplace. Stimulants are historically the most commonly prescribed class of medications for ADHD and accounted for approximately 90% of all ADHD medication prescriptions in the United States during the year ended September 30, 2025.
Read the full filing description · filed 18 Mar 2026
At a glance
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
Source: SEC filings. Information and analytics, not investment advice.